Dr. Jain on the Activity of Venetoclax in MCL

Preetesh Jain, MD, PhD, clinical fellow in medical oncology at The University of Texas MD Anderson Cancer Center, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

In a single-center phase 1 study, investigators evaluated the activity of venetoclax in patients with MCL. In the trial, investigators reached a dose of 800 mg.

The highest complete remission rate of 21% was reported in the cohort of patients with MCL, says Jain. These data speak to the activity of venetoclax in MCL, despite the fact that these patients had not progressed on a BTK inhibitor, concludes Jain.